Edition:
United Kingdom

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

7.09USD
24 Apr 2018
Change (% chg)

$-0.11 (-1.53%)
Prev Close
$7.20
Open
$7.33
Day's High
$7.33
Day's Low
$6.99
Volume
371,507
Avg. Vol
242,738
52-wk High
$14.45
52-wk Low
$5.02

Select another date:

Wed, Apr 18 2018

BRIEF-Bellicum Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

* BELLICUM PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Bellicum Pharmaceuticals Announces Proposed Public Offering Of Common Stock

* BELLICUM PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Bellicum Announces Clinical Hold Lifted On U.S. Studies Of BPX-501

* BELLICUM ANNOUNCES CLINICAL HOLD LIFTED ON U.S. STUDIES OF BPX-501

BRIEF-Bellicum Pharmaceuticals Reports Qtrly Loss Per Share $0.66

* BELLICUM PHARMACEUTICALS PROVIDES OPERATIONAL UPDATE AND REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017

BRIEF-Bellicum Announces Interim Results Showing Low Rates Of Cancer Recurrence In Pediatric AML Patients Treated With BPX-501

* BELLICUM ANNOUNCES INTERIM RESULTS SHOWING LOW RATES OF CANCER RECURRENCE IN PEDIATRIC AML PATIENTS TREATED WITH BPX-501

BRIEF-Bellicum Pharma Says Effective Feb 20, Board Approved Increase In Size Of Board To 8 Members

* BELLICUM PHARMA SAYS EFFECTIVE FEB 20, BOARD APPROVED INCREASE IN SIZE OF BOARD TO 8 MEMBERS - SEC FILING Source text: (http://bit.ly/2BMB6hN) Further company coverage:

BRIEF-Bellicum Announces Update On Clinical Hold Of U.S. BPX-501 Studies

* BELLICUM ANNOUNCES UPDATE ON CLINICAL HOLD OF U.S. BPX-501 STUDIES

Bellicum's cancer drug trials on clinical hold, shares tumble

Bellicum Pharmaceuticals Inc said the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of the company's experimental cancer drug after three cases of brain disease linked to head trauma.

Bellicum's cancer drug trials on clinical hold, shares tumble

Jan 30 Bellicum Pharmaceuticals Inc said the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of the company's experimental cancer drug after three cases of brain disease linked to head trauma.

BRIEF-Bellicum Pharmaceuticals Announces Clinical Hold On BPX-501 Clinical Trials In U.S.

* BELLICUM PHARMACEUTICALS ANNOUNCES CLINICAL HOLD ON BPX-501 CLINICAL TRIALS IN THE UNITED STATES

Select another date: